Showing results (161-170 of 254) with videos related to
Sort By:
Pageof 26
Journal of the American Academy of Dermatology|February 21, 2006
Relapse, rebound, and psoriasis adverse events: an advisory group reportWayne Carey, Scott Glazer, Alice B Gottlieb, et al.Journal of Drugs in Dermatology : JDD|August 13, 2015
Reproducible Novel Transcriptional Differences Between Psoriatic Lesional and Non-Lesional Skin Show Increased Inflammation and MetabolismDaniel J Aires, Graham Rockwell, Alan Menter, et al.The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.Journal of Drugs in Dermatology : JDD|January 14, 2009
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populationsAlan Menter, Kristian Reich, Alice B Gottlieb, et al.Physiological Genomics|March 20, 2003
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide arrayXianghong Zhou, James G Krueger, Ming-Chih J Kao, et al.Cutis|November 24, 2011
An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasisCharles P Hudson, Steven Kempers, Alan Menter, et al.JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.Cutis|September 1, 2011
An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasisAlan Menter, Howard Sofen, Stacy Smith, et al.The Journal of Dermatological Treatment|March 23, 2018
Prevalence of genital psoriasis in patients with psoriasisKim A P Meeuwis, Alison Potts Bleakman, Peter C M van de Kerkhof, et al.International Journal of Dermatology|June 7, 2007
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb studyAlan Menter, Tiffani K Hamilton, Darryl P Toth, et al.Pageof 26